immune checkpoint inhibitor therapy

Patrick DalyNon-Small Cell Lung Cancer | September 21, 2023

JK5G postbiotics may improve gut microbiota, QOL, and appetite in patients with advanced NSCLC on PD-1 inhibitor therapy.

Patrick DalyOncology | September 12, 2023

In ESMO Open, Enrique Grande, MD, and collaborating researchers published findings from the IMMUNOSUN trial on the ...

Patrick DalySmall Cell Lung Cancer | September 21, 2023

Immune checkpoint inhibitors (ICIs) are approved for treatment of small cell lung cancer (SCLC). However, according to ...

Patrick DalySkin Cancer | November 7, 2024

In a recent article, published in the Journal of Cancer Research and Clinical Oncology, researchers examined the protein ...

Rebecca AraujoNon-Small Cell Lung Cancer | September 21, 2023

Adoptive cell therapy in combination with checkpoint inhibitors may be promising new treatment for patients with ...

Victoria SochaASCO 2019 | April 25, 2023

Immune Checkpoint Therapy plus Cytoreductive Surgery in mRCC ...

Victoria SochaASCO 2019 | April 25, 2023

Immune Checkpoint Inhibitor Response in Patients with mRCC ...

Rob DillardBreast Cancer News | March 26, 2025

The efficacy of immune checkpoint blockage therapy (ICB) in treating triple negative breast cancer (TNBC) may vary with ...

Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023

A phase I/Ib study published in Clinical Cancer Research found that treatment with the immune checkpoint inhibitor ...

Kaitlyn D’OnofrioRheumatology | September 12, 2023

A study published in Arthritis & Rheumatology analyzed rheumatic immune‐related adverse effects ...